GlobeNewswire Inc | Jan 4, 2021 08:00AM EST

January 04, 2021

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in January:

-- H.C. Wainwright Virtual BioConnect Conference on Monday, January 11, 2021: A pre-recorded fireside chat with Dr. Nichtberger will be available on the companys website at 6:00 a.m. ET. -- Stern Investor Relations Corporate Access Event on Monday, January 11, 2021: A pre-recorded fireside chat with Dr. Nichtberger will be available on the companys website at 7:00 a.m. ET.

All webcasts of presentations are available on the News and Events section of the companys website at www.cabalettabio.com. Following the presentations, a replay of the webcasts will be available on the website for 90 days.

About Cabaletta BioCabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabalettas proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Companys lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTesphase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Companys lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:Anup MardaChief Financial Officerinvestors@cabalettabio.com

Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.com